MTOR and lymphangioleiomyomatosis: For this reason, the American Thoracic Society and the Japanese Respiratory Society suggested that the clinical outcomes derived from the combination of doxycycline with mTOR inhibitors and hormonal therapy, which are already used in LAM patients, be deepened [28].